USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
IIEKKING G DOUG reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Financial Officer, Doug G. Iieekking, received a grant of 41,639 restricted stock units on February 19, 2026. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
The award vests in stages, with 25% of the units vesting on each 19th of February thereafter. Following this grant, the officer directly holds 83,218 restricted stock units, aligning a portion of his compensation with the company’s future share performance.
USANA Health Sciences CEO Kevin Guest reported an equity award. On February 19, 2026, he acquired 82,726 restricted stock units at a stated price of $0.00 per unit. Each unit is a contingent right to receive one share of USANA common stock.
The restricted stock units vest 25% on each 19th of February thereafter under the grant terms. Following this award, Guest directly held a total of 135,062 restricted stock units in USANA.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed dispositions of Common Stock of USNA. The filing lists 4,461 shares across three restricted-stock lots dated 02/06/2026 (1,628), 02/07/2026 (822) and 02/08/2026 (2,011).
USANA Health Sciences reported mixed 2025 results, with revenue up but profits down sharply. Fiscal 2025 net sales rose to $925.3 million from $854.5 million, but net earnings fell to $10.8 million from $42.0 million, and diluted EPS dropped to $0.58 from $2.19. Adjusted diluted EPS declined to $1.93 from $2.59, while Adjusted EBITDA slipped to $101.3 million from $110.3 million.
In Q4 2025, net sales were $226.2 million versus $213.6 million a year earlier, but the company posted a $1.8 million net loss, driven by a $7.0 million non‑cash impairment and $6.5 million of cost‑realignment charges, partly offset by a $3.2 million asset sale gain. Active customers in the core nutritional business declined to 387,000 from 454,000, while Hiya and Rise Wellness delivered strong growth.
For fiscal 2026, USANA guides to modest top-line growth and improved profitability. It projects consolidated net sales between $925 million and $1.0 billion, net earnings of $20.3–$26.6 million, diluted EPS of $1.11–$1.45, adjusted diluted EPS of $1.95–$2.29, and Adjusted EBITDA of $101.3–$109.3 million. The balance sheet shows $158 million of cash and $14 million of debt, after repurchasing 927,000 shares for $28 million in 2025.
USANA Health Sciences filed an amended report to detail compensation changes tied to its CEO transition. Former CEO Jim Brown will serve as a strategic advisor through December 31, 2026, receiving his $825,000 base salary, 2025 bonus, and standard employee benefits during this period.
After his advisory role ends, Brown is entitled to $1,500,000 in severance, paid in three $500,000 installments in 2027, 2028, and 2029, plus 18 months of company-paid COBRA benefits, in exchange for a release of claims and ongoing restrictive covenants. Unvested equity awards at separation will be cancelled.
Returning CEO Kevin Guest will receive an $850,000 base salary, a target annual bonus equal to 100% of salary, a 2026 RSU grant with a $1,700,000 grant date value, and standard benefit and savings plans. He also received a long-term performance award, payable in company shares after a four-year period ending January 1, 2030, if USANA’s stock delivers positive total shareholder return and outperforms the Russell 2000 Index by specified levels, with potential payouts from $850,000 up to $3,400,000.
USANA Health Sciences chief information officer Benedict Peter reported multiple equity transactions in early February 2026. On three dates, restricted stock units converted into common shares at an exercise price of $0, increasing his directly held common stock and reducing his RSU balance.
Across these transactions, some common shares were disposed of at $21.34 per share under transaction code F, leaving Peter with 1,821 shares of USANA common stock and 20,733 restricted stock units held directly after the reported activity.
USANA Health Sciences chief operating officer Walter Noot reported routine equity compensation activity over three days in early February 2026. He exercised restricted stock units (RSUs) into common shares and had a portion of those shares withheld to cover tax obligations at a price of $21.34 per share.
On February 6, 7, and 8, 2026, RSU conversions delivered 3,375, 1,705, and 4,058 common shares, respectively, while 1,609, 813, and 1,738 shares were withheld for taxes. After these transactions, Noot directly held 4,978 shares of common stock and 41,179 RSUs.
USANA Health Sciences Chief Commercial Officer Brent Neidig reported multiple stock transactions over three days in February 2026 related to vested restricted stock units (RSUs). On February 6, 2026, 2,219 RSUs were converted into common stock, with 1,102 common shares disposed of at $21.34 per share, leaving 1,117 common shares directly held after that date.
On February 7, 2026, a further 1,401 RSUs were converted into common stock, with 696 common shares disposed of at $21.34 per share, resulting in 1,822 directly held common shares. On February 8, 2026, 3,690 RSUs were converted, with 1,753 common shares disposed of at $21.34 per share and 3,759 common shares directly held afterward.
Following these transactions, Neidig directly held 3,759 shares of common stock and 36,584 RSUs. Each RSU represents a contingent right to receive one share of USANA common stock, and the RSUs vest in 25% increments on the anniversaries of February 6, 2023, February 7, 2022, and February 8, 2024, as applicable.
USANA Health Sciences chief people officer Paul A. Jones reported several equity compensation transactions in early February 2026. On February 6, 7 and 8, 2026, restricted stock units converted into common stock in amounts of 2,174, 1,372 and 2,514 shares at an exercise price of $0 per share.
On each of those dates, portions of common stock were disposed of in transactions coded "F" in amounts of 754, 476 and 872 shares at a price of $21.34 per share. Following these transactions, Jones directly owned 9,127 shares of USANA common stock and 25,585 restricted stock units, each RSU representing a contingent right to receive one share as they vest on specified anniversary dates.
USANA Health Sciences Chief Financial Officer Doug G. Iie kking reported multiple equity transactions over February 6–8, 2026. On each date, restricted stock units were exercised for 3,532, 2,231, and 4,084 shares of common stock, respectively, at an exercise price of $0 per share.
Related dispositions of common stock at $21.34 per share totaled 2,567, 1,612, and 2,746 shares on the same dates. Following these transactions, the officer directly held 2,922 shares of common stock and 41,579 restricted stock units, each representing the right to receive one share of USNA common stock.